Copyright © 2014 EnBiotix, Inc.. All Rights Reserved

The EnBiotix Board of Directors brings together over a century of combined Biotech Management and Executive experience

Jeffrey Wager, M.D., Chairman

Jeffrey Wager has over 20 years of senior operating experience in the life sciences, including Medical Science Partners, a Harvard sponsored VC fund focused on startups spinning out of the Harvard medical system; forming Apeiron Partners LLC to focus on designing/executing corporate spin-outs, having successfully completed six to date, including Targacept, Inc. (NASD:TRGT) and Artisan Pharma, Inc., including the latter, where, from 2006 – 2010 he was its founding CEO, raising >$50 million, building the team and implementing a 750 patient, 17 country Phase 2b study leading to its acquisition by Asahi in 2011.

Dennis Ausiello, M.D., Director

Dennis A. Ausiello, MD, is the Jackson Professor of Clinical Medicine at Harvard Medical School, and chief of Medicine at Massachusetts General Hospital (MGH).  A nationally recognized leader in academic medicine, Ausiello was elected to the Institute of Medicine of the National Academy of Science in 1999 and the American Academy of Arts and Sciences in 2003. He has written for the New York Times, the Wall Street Journal and the Boston Globe on health subjects, including human genetics, clinical trials and the relationship between the academy and industry.  He also sits on the Board of Directors of Pfizer.

Dan Hartman, M.D., Director

Dan Hartman, M.D. is a board member and co-founder of Enbiotix. He joined the Bill and Melinda Gates Foundation in 2012 as the Director of Integrated Development and leads a team that provides technical expertise in drug and diagnostic development. Dr. Hartman has extensive management and pharmaceutical experience and joined the foundation after four years as President and CEO of Great Lakes Development Inc.–a consulting company providing strategic and operational support for early drug development projects. Previously, Dr. Hartman served as Senior Vice President of Product Development at deCODE genetics, Executive Director of Pfizer Global Research and Development, and Vice President of Global Clinical Development at Esperion Therapeutics.

Christopher Micetich, Director

Christopher G. Micetich serves as Board Chairman and President & CEO of Naeja Pharmaceuticals Inc. and more recently founded Fedora Pharmaceuticals Inc. He has over 25 years of senior operating experience in the pharmaceutical industry and is the principal founder of several start-up companies. In January 2012, Christopher founded a new company called Fedora Pharmaceuticals Inc. established to develop novel and clinically important classes of Beta-Lactamase Inhibitors.

Michael Pratt, Observer

Mr. Pratt is currently serving as Interim Managing Director of the BU Office of Technology Development.  As Executive Director Business Development he led a team of business development professionals across all technical fields to connect Boston University discoveries with commercial opportunities.  Prior to OTD, Mr. Pratt was the Global Support Manager at NESLAB Instruments, Inc. of Portsmouth New Hampshire. Mr. Pratt holds a BA in Physics from the College of the Holy Cross and an MBA from Boston University. He is a member of the Licensing Executives Society and the Association of University Technology Managers (AUTM)